| 000 | 01614 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250516143636.0 | ||
| 264 | 0 | _c20140919 | |
| 008 | 201409s 0 0 eng d | ||
| 022 | _a1755-5922 | ||
| 024 | 7 |
_a10.1111/1755-5922.12033 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHadi, Najah R | |
| 245 | 0 | 0 |
_aRole of NF-κβ and oxidative pathways in atherosclerosis: cross-talk between dyslipidemia and candesartan. _h[electronic resource] |
| 260 |
_bCardiovascular therapeutics _cDec 2013 |
||
| 300 |
_a381-7 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAngiotensin II Type 1 Receptor Blockers _xtherapeutic use |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAtherosclerosis _xdrug therapy |
| 650 | 0 | 4 |
_aBenzimidazoles _xpharmacology |
| 650 | 0 | 4 | _aBiphenyl Compounds |
| 650 | 0 | 4 |
_aCell Movement _xdrug effects |
| 650 | 0 | 4 |
_aChemokines _xanalysis |
| 650 | 0 | 4 |
_aCytokines _xanalysis |
| 650 | 0 | 4 |
_aDyslipidemias _xdrug therapy |
| 650 | 0 | 4 |
_aLipids _xblood |
| 650 | 0 | 4 |
_aMonocytes _xdrug effects |
| 650 | 0 | 4 |
_aNF-kappa B _xphysiology |
| 650 | 0 | 4 | _aOxidation-Reduction |
| 650 | 0 | 4 | _aRabbits |
| 650 | 0 | 4 |
_aTetrazoles _xpharmacology |
| 650 | 0 | 4 |
_aVascular Cell Adhesion Molecule-1 _xanalysis |
| 700 | 1 | _aYousif, Nasser Ghaly | |
| 700 | 1 | _aAbdulzahra, Mohammed S | |
| 700 | 1 | _aMohammad, Bassim I | |
| 700 | 1 | _aAl-Amran, Fadhil G | |
| 700 | 1 | _aMajeed, Murooge L | |
| 700 | 1 | _aYousif, Maitham G | |
| 773 | 0 |
_tCardiovascular therapeutics _gvol. 31 _gno. 6 _gp. 381-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/1755-5922.12033 _zAvailable from publisher's website |
| 999 |
_c22650430 _d22650430 |
||